Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/3/2026Positive
HRMY
Harmony Biosciences HoldingsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.46B
P/E Ratio
13.67
EPS
$3.09
Beta
0.93
52W High
$43.49
52W Low
$25.52
50-Day MA
$37.56
200-Day MA
$34.23
Dividend Yield
—
Profit Margin
18.90%
Forward P/E
10.39
PEG Ratio
—
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Fundamentals
| Revenue (TTM) | $959.90M |
| Gross Profit (TTM) | $723.99M |
| EBITDA | $255.99M |
| Operating Margin | 34.20% |
| Return on Equity | 20.50% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $16.63 |
| Book Value | $17.19 |
| Price-to-Book | 2.44 |
| Price-to-Sales (TTM) | 2.56 |
| EV/Revenue | 2.004 |
| EV/EBITDA | 6.87 |
| Quarterly Earnings Growth (YoY) | 88.20% |
| Quarterly Revenue Growth (YoY) | 30.30% |
| Shares Outstanding | $58.24M |
| Float | $52.08M |
| % Insiders | 11.63% |
| % Institutions | 99.72% |
Historical Volatility
HV 10-Day
33.84%
HV 20-Day
35.79%
HV 30-Day
39.16%
HV 60-Day
42.55%
HV Rank
53.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($47.36 target)
2
Strong Buy5
Buy3
Hold1
Strong SellLatest News
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.
GlobeNewsWire9/3/2026Neutral
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.
GlobeNewsWire8/27/2026Neutral
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
MarketBeat8/14/2026Positive
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
Zacks Investment Research8/7/2026Positive
4 Stocks Trading Near 52-Week High With More Upside Potential
Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.
Zacks Investment Research8/6/2026Positive
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.
GlobeNewsWire8/6/2026Neutral
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated
Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.
Seeking Alpha8/5/2026Positive
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.
Zacks Investment Research8/5/2026Positive
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research8/5/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HRMY and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026